Browse by category

BioAge axes STRIDES trial evaluating azelaprag in combination with tirzepatide for the treatment of obesity

BioAge Labs is to discontinue the ongoing STRIDES Phase 2 study of its investigational drug candidate azelaprag as monotherapy and in...

SURMOUNT-5: Zepbound superior to Wegovy in head-to-head trial showing an average weight loss of 20.2% vs. 13.7%

Eli Lilly and Company has announced topline results from the SURMOUNT-5 phase 3b open-label randomised clinical trial that found Zepbound...

Adults with pre-diabetes and obesity or overweight treated with tirzepatide had sustained weight loss and nearly 99% remained diabetes-free at 176 weeks

Results from the Phase 3 SURMOUNT-1 three-year study (176-week treatment period), the longest completed study to date of tirzepatide,...

Palatin completes study enrolment of bremelanotide plus tirzepatide to treat obesity

Palatin Technologies has completed enrolment in the study entitled "BMT-801, A Phase II, Randomized, Double-Blind, Placebo-Controlled,...

Tirzepatide results in greater weight loss in women than men

All doses of tirzepatide consistently reduced body weight in women and men, but women experienced greater weight loss, according to post...

Large-scale population analysis confirms safety profile of tirzepatide

An analysis of real-world evidence from the FDA Adverse Event Reporting System (FAERS) database of tirzepatide, presented at this year's...

Journal Watch 10/7/2024

Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...

Patients receiving tirzepatide were significantly more likely to achieve clinically meaningful weight loss compared with those treated receiving semaglutide

Individuals with overweight or obesity treated with tirzepatide were significantly more likely to achieve clinically meaningful weight...

Tirzepatide associated with a potential targeted effect on visceral fat and liver fat

Exploratory analysis from the SURPASS-3 MRI study has shown a significant reduction of both visceral- and liver fat z-scores, and a shift...

Semaglutide and tirzepatide decrease cravings and reduce alcohol consumption

An analysis of social media posts and a remote study of individuals with obesity who reported using semaglutide and tirzepatide, has...

Preoperative antihypertensive drugs and visceral fat area can predict hypertension remission and recurrence post-LSG

4 days ago

Muscle-preserving weight loss drug ASC47 plus semaglutide is superior to semaglutide monotherapy for weight loss

4 days ago

Racial and ethnic groups face barriers to obtaining OMMs

4 days ago

Browse by category

Browse by tag

Weekly Digest

Get a round-up of the main headlines from Bariatric News, directly to your inbox each week.

Get in touch!
Email: info@bariatricnews.net